Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | AMLX |
---|---|---|
09:32 ET | 9755 | 5.35 |
09:34 ET | 6985 | 5.375 |
09:36 ET | 2573 | 5.32 |
09:38 ET | 2580 | 5.37 |
09:39 ET | 8344 | 5.38 |
09:41 ET | 3050 | 5.42 |
09:43 ET | 5961 | 5.42 |
09:45 ET | 2670 | 5.375 |
09:48 ET | 1794 | 5.365393 |
09:50 ET | 6596 | 5.3288 |
09:52 ET | 5030 | 5.32 |
09:54 ET | 2499 | 5.31 |
09:56 ET | 1100 | 5.33 |
09:57 ET | 1923 | 5.3219 |
09:59 ET | 7009 | 5.35 |
10:01 ET | 6726 | 5.3001 |
10:03 ET | 6600 | 5.3094 |
10:06 ET | 7894 | 5.2989 |
10:08 ET | 4401 | 5.295 |
10:10 ET | 4586 | 5.2794 |
10:12 ET | 3640 | 5.3 |
10:14 ET | 638 | 5.295 |
10:15 ET | 3836 | 5.28 |
10:17 ET | 2316 | 5.2808 |
10:19 ET | 857 | 5.295 |
10:21 ET | 4923 | 5.33 |
10:24 ET | 2194 | 5.345 |
10:26 ET | 1064 | 5.36 |
10:28 ET | 1983 | 5.335 |
10:30 ET | 2122 | 5.35 |
10:32 ET | 1229 | 5.33 |
10:33 ET | 5524 | 5.325 |
10:35 ET | 3000 | 5.305 |
10:37 ET | 600 | 5.3 |
10:39 ET | 791 | 5.3075 |
10:42 ET | 2960 | 5.32 |
10:44 ET | 2065 | 5.335 |
10:46 ET | 2239 | 5.35 |
10:48 ET | 2093 | 5.3499 |
10:50 ET | 585 | 5.345 |
10:51 ET | 2927 | 5.355 |
10:53 ET | 1150 | 5.36 |
10:55 ET | 2200 | 5.36 |
10:57 ET | 1077 | 5.36 |
11:00 ET | 3192 | 5.355 |
11:02 ET | 809 | 5.34 |
11:04 ET | 5253 | 5.315 |
11:06 ET | 2582 | 5.3299 |
11:08 ET | 6811 | 5.3001 |
11:09 ET | 4433 | 5.3 |
11:11 ET | 6034 | 5.295 |
11:13 ET | 1100 | 5.275 |
11:15 ET | 1218 | 5.2775 |
11:18 ET | 300 | 5.275 |
11:20 ET | 754 | 5.2801 |
11:22 ET | 1600 | 5.305 |
11:24 ET | 299 | 5.31 |
11:26 ET | 3059 | 5.32 |
11:27 ET | 600 | 5.315 |
11:29 ET | 2100 | 5.3 |
11:31 ET | 1735 | 5.305 |
11:33 ET | 3855 | 5.285598 |
11:36 ET | 7290 | 5.2999 |
11:38 ET | 1000 | 5.315 |
11:40 ET | 2273 | 5.335 |
11:42 ET | 8633 | 5.3112 |
11:44 ET | 1200 | 5.325 |
11:45 ET | 2154 | 5.335 |
11:47 ET | 1200 | 5.33 |
11:49 ET | 2696 | 5.325 |
11:51 ET | 700 | 5.325 |
11:54 ET | 4006 | 5.305 |
11:56 ET | 1131 | 5.315 |
11:58 ET | 4911 | 5.3105 |
12:00 ET | 3173 | 5.315 |
12:02 ET | 1820 | 5.335 |
12:03 ET | 2824 | 5.3538 |
12:05 ET | 3102 | 5.35 |
12:07 ET | 4006 | 5.355 |
12:09 ET | 2684 | 5.365 |
12:12 ET | 3651 | 5.36 |
12:14 ET | 1350 | 5.355 |
12:16 ET | 1878 | 5.365 |
12:18 ET | 706 | 5.37 |
12:20 ET | 5422 | 5.375 |
12:21 ET | 3021 | 5.38 |
12:23 ET | 3401 | 5.395 |
12:25 ET | 6730 | 5.415 |
12:27 ET | 20316 | 5.405 |
12:30 ET | 4654 | 5.42 |
12:32 ET | 8325 | 5.4209 |
12:34 ET | 5977 | 5.445 |
12:36 ET | 1700 | 5.4412 |
12:38 ET | 6068 | 5.44 |
12:39 ET | 800 | 5.4451 |
12:41 ET | 2207 | 5.45 |
12:43 ET | 7424 | 5.485 |
12:45 ET | 10887 | 5.515 |
12:48 ET | 13415 | 5.53 |
12:50 ET | 10608 | 5.505 |
12:52 ET | 1791 | 5.51 |
12:54 ET | 8924 | 5.5 |
12:56 ET | 6571 | 5.5 |
12:57 ET | 2417 | 5.4958 |
12:59 ET | 2834 | 5.505 |
01:01 ET | 1998 | 5.5064 |
01:03 ET | 15877 | 5.515 |
01:06 ET | 4428 | 5.5008 |
01:08 ET | 1050 | 5.505 |
01:10 ET | 1901 | 5.505 |
01:12 ET | 6602 | 5.4961 |
01:14 ET | 5658 | 5.465 |
01:15 ET | 9668 | 5.4401 |
01:17 ET | 2536 | 5.445 |
01:19 ET | 2490 | 5.4499 |
01:21 ET | 1875 | 5.445 |
01:24 ET | 2772 | 5.445 |
01:26 ET | 2468 | 5.46 |
01:28 ET | 3947 | 5.4493 |
01:30 ET | 1840 | 5.455 |
01:32 ET | 2824 | 5.455 |
01:33 ET | 1620 | 5.45 |
01:35 ET | 2061 | 5.4499 |
01:37 ET | 2069 | 5.445 |
01:39 ET | 1595 | 5.44 |
01:42 ET | 2400 | 5.425 |
01:44 ET | 3006 | 5.425 |
01:46 ET | 500 | 5.43 |
01:48 ET | 1718 | 5.425 |
01:50 ET | 3966 | 5.415 |
01:51 ET | 1093 | 5.42 |
01:53 ET | 639 | 5.42 |
01:55 ET | 700 | 5.44 |
01:57 ET | 2389 | 5.435 |
02:00 ET | 1200 | 5.44 |
02:02 ET | 1359 | 5.445 |
02:04 ET | 2200 | 5.445 |
02:06 ET | 1093 | 5.445 |
02:08 ET | 18989 | 5.425 |
02:09 ET | 27839 | 5.475 |
02:11 ET | 1525 | 5.4899 |
02:13 ET | 16298 | 5.48 |
02:15 ET | 2980 | 5.485 |
02:18 ET | 2700 | 5.485 |
02:20 ET | 1580 | 5.475 |
02:22 ET | 1086 | 5.48 |
02:24 ET | 6354 | 5.45 |
02:26 ET | 6197 | 5.4345 |
02:27 ET | 400 | 5.4337 |
02:29 ET | 5255 | 5.445 |
02:31 ET | 645 | 5.45 |
02:33 ET | 2192 | 5.455 |
02:36 ET | 1500 | 5.445 |
02:38 ET | 900 | 5.455 |
02:40 ET | 1147 | 5.455 |
02:42 ET | 1900 | 5.445 |
02:44 ET | 40910 | 5.395 |
02:45 ET | 2260 | 5.405 |
02:47 ET | 5113 | 5.42 |
02:49 ET | 1948 | 5.42 |
02:51 ET | 1619 | 5.41 |
02:54 ET | 2795 | 5.41 |
02:56 ET | 1976 | 5.425 |
02:58 ET | 7868 | 5.405 |
03:00 ET | 5700 | 5.41 |
03:02 ET | 2857 | 5.41 |
03:03 ET | 16155 | 5.435 |
03:05 ET | 17479 | 5.425 |
03:07 ET | 17132 | 5.4502 |
03:09 ET | 1927 | 5.455 |
03:12 ET | 500 | 5.455 |
03:14 ET | 500 | 5.4599 |
03:16 ET | 9302 | 5.44 |
03:18 ET | 3583 | 5.43 |
03:20 ET | 2150 | 5.43 |
03:21 ET | 3700 | 5.425 |
03:23 ET | 3974 | 5.42 |
03:25 ET | 1353 | 5.43 |
03:27 ET | 763 | 5.425 |
03:30 ET | 4903 | 5.415 |
03:32 ET | 4005 | 5.4 |
03:34 ET | 3653 | 5.4 |
03:36 ET | 1932 | 5.405 |
03:38 ET | 2187 | 5.41 |
03:39 ET | 1006 | 5.405 |
03:41 ET | 850 | 5.405 |
03:43 ET | 2119 | 5.405 |
03:45 ET | 11906 | 5.405 |
03:48 ET | 3116 | 5.415 |
03:50 ET | 3007 | 5.405 |
03:52 ET | 7140 | 5.405 |
03:54 ET | 7564 | 5.396748 |
03:56 ET | 5460 | 5.395 |
03:57 ET | 6143 | 5.395 |
03:59 ET | 81891 | 5.4 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Amylyx Pharmaceuticals Inc | 358.8M | -2.2x | --- |
Organogenesis Holdings Inc | 383.1M | -22.2x | --- |
Amarin Corporation PLC | 247.4M | -7.1x | --- |
Ironwood Pharmaceuticals Inc | 662.9M | 91.4x | --- |
Sinovac Biotech Ltd | 639.9M | -4.9x | --- |
Voyager Therapeutics Inc | 373.0M | 44.5x | --- |
Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery and development of treatments for neurodegenerative diseases. The Company is focused on the development and commercialization of its product candidate: AMX0035 for the treatment of Wolfram syndrome and for the treatment of progressive supranuclear palsy, and AMX0114, the Company’s antisense oligonucleotide targeting calpain-2 for the treatment of amyotrophic lateral sclerosis (ALS). AMX0035 is a dual-unfolded protein response (UPR)-Bax apoptosis inhibitor composed of PB and TURSO (also known as TUDCA). The Company’s Avexitide is an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist that has been evaluated in five clinical trials for post-bariatric hypoglycemia (PBH) and has also been studied in congenital hyperinsulinism (HI), two indications characterized by hyperinsulinemic hypoglycemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $358.8M |
---|---|
Revenue (TTM) | $298.8M |
Shares Outstanding | 68.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.45 |
Book Value | $6.40 |
P/E Ratio | -2.2x |
Price/Sales (TTM) | 1.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -59.50% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.